NC
Live price temporarily unavailable.
Price history
NuCana (NCNA) is a Health Care company. Latest news and coverage below.
IPO: September 28, 2017 · $15.00 offering · NASDAQ · View IPO details →
NuCana net income history (FY2016–FY2025)
Net income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −£8.45M | −£25.7M | −£19.1M | −£26.7M | −£36.4M | −£47.9M | −£39.1M | −£32.8M | −£22.8M | −£20.1M |
| Net income | −£6.05M | −£23.1M | −£13.8M | −£21.4M | −£30.7M | −£40.5M | −£32.0M | −£27.6M | −£19.0M | −£29.4M |
| EPS (diluted) | −£0.25 | −£0.89 | −£0.43 | −£0.66 | −£0.81 | −£0.78 | −£0.61 | −£0.53 | −£0.26 | £0.00 |
| Balance sheet | ||||||||||
| Cash and equivalents | £20.0M | £86.7M | £77.0M | £52.0M | £87.4M | £60.3M | £41.9M | £17.2M | £6.75M | £24.3M |
| Total assets | £27.2M | £96.4M | £87.2M | £70.3M | £107.8M | £77.5M | £58.3M | £27.8M | £14.8M | £29.8M |
| Total liabilities | £1.97M | £2.94M | £5.59M | £6.75M | £8.56M | £11.9M | £19.8M | £12.9M | £8.82M | £5.51M |
| Shareholders' equity | £25.2M | £93.4M | £81.6M | £63.5M | £99.2M | £65.5M | £38.5M | £14.9M | £5.95M | £24.3M |
| Cash flow | ||||||||||
| Operating cash flow | −£9.26M | −£8.71M | −£12.2M | −£23.8M | −£21.6M | −£23.8M | −£23.2M | −£26.4M | −£19.1M | −£7.47M |
| Capital expenditure | £15.0K | £370.0K | £210.0K | £46.0K | £361.0K | £64.0K | £12.0K | £4.00K | £4.00K | £0 |
| Free cash flow | −£9.28M | −£9.08M | −£12.4M | −£23.9M | −£22.0M | −£23.9M | −£23.2M | −£26.4M | −£19.1M | −£7.47M |
Net income
| Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −£6.28M | — | −£8.27M | −£8.35M | — | −£2.85M | −£11.8M | — |
| Net income | −£5.41M | — | −£6.84M | −£7.00M | — | −£2.47M | −£24.1M | — |
| EPS (diluted) | −£0.10 | — | −£0.13 | −£0.12 | — | −£0.01 | £0.00 | — |
| Balance sheet | ||||||||
| Cash and equivalents | £24.6M | £17.2M | — | £11.6M | £6.75M | — | £8.44M | £24.3M |
| Total assets | £41.3M | £27.8M | — | £20.1M | £14.8M | — | £16.2M | £29.8M |
| Total liabilities | £13.9M | £12.9M | — | £16.3M | £8.82M | — | £8.83M | £5.51M |
| Shareholders' equity | £27.4M | £14.9M | — | £3.80M | £5.95M | — | £7.38M | £24.3M |
From NuCana's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in British Pound (GBP), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About NuCana
- Headquarters
- Edinburgh, United Kingdom From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International